- Home
- OPT vs HYB Comparison
OPT vs HYB Comparison
Compare OPT & HYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- HYB
- Stock Information
- Founded
- OPT 1984
- HYB 1987
- Country
- OPT Australia
- HYB United States
- Employees
- OPT N/A
- HYB N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- HYB Investment Managers
- Sector
- OPT Health Care
- HYB Finance
- Exchange
- OPT Nasdaq
- HYB Nasdaq
- Market Cap
- OPT 201.5M
- HYB 193.3M
- IPO Year
- OPT 2020
- HYB 1999
- Fundamental
- Price
- OPT $3.24
- HYB $8.27
- Analyst Decision
- OPT Strong Buy
- HYB
- Analyst Count
- OPT 2
- HYB 0
- Target Price
- OPT $14.00
- HYB N/A
- AVG Volume (30 Days)
- OPT 10.8K
- HYB 39.6K
- Earning Date
- OPT 08-30-2024
- HYB 01-01-0001
- Dividend Yield
- OPT N/A
- HYB 6.67%
- EPS Growth
- OPT N/A
- HYB N/A
- EPS
- OPT N/A
- HYB N/A
- Revenue
- OPT $261,859.00
- HYB N/A
- Revenue This Year
- OPT N/A
- HYB N/A
- Revenue Next Year
- OPT $55,563.16
- HYB N/A
- P/E Ratio
- OPT N/A
- HYB N/A
- Revenue Growth
- OPT N/A
- HYB N/A
- 52 Week Low
- OPT $1.60
- HYB $6.23
- 52 Week High
- OPT $4.40
- HYB $7.41
- Technical
- Relative Strength Index (RSI)
- OPT 70.30
- HYB 67.28
- Support Level
- OPT $2.84
- HYB $8.22
- Resistance Level
- OPT $3.19
- HYB $8.41
- Average True Range (ATR)
- OPT 0.14
- HYB 0.08
- MACD
- OPT 0.01
- HYB -0.03
- Stochastic Oscillator
- OPT 100.00
- HYB 46.43
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed‐end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.